When RFK Jr. stood up in February 2026 and announced that a ketogenic diet could “cure schizophrenia,” the backlash was swift and predictable. Clinicians pushed back hard, calling it an overstatement of preliminary evidence. Headlines got loud. And somewhere in all of that noise, a genuinely interesting story got buried: the science behind using ketogenic therapy for serious mental illness is moving faster than most people realize, and the researchers doing this work are at places like Harvard, Stanford, and the University of Edinburgh.

If you heard the RFK claim and felt something between hope and skepticism, that’s probably the right place to land. You might be wondering what’s actually true. Here’s what I’d tell you.

What RFK Got Wrong, and What He Got Accidentally Right

The word “cure” was the problem. It’s not a word any serious researcher in this space is using, and it wasn’t supported by the studies RFK cited, which focused on bipolar disorder, not schizophrenia specifically. Pharmacy Times noted in February 2026 that clinicians were broadly uncomfortable with the framing, and rightly so. A single dietary intervention curing a complex, heterogeneous condition like schizophrenia is not what the evidence shows.

But strip away the overclaiming, and there is something real underneath. A pilot trial led by Stanford psychiatrist Dr. Shebani Sethi followed 21 adults with bipolar disorder or schizophrenia through four months on a ketogenic diet. Participants showed a 32% improvement on the Brief Psychiatric Rating Scale and a 31% improvement in overall Clinical Global Impression severity scores. Those aren’t trivial numbers in a population that is notoriously difficult to treat and often doesn’t respond fully to medication. They’re also preliminary, from a small sample, without a control group. Both things are true at once.

The Field That Quietly Built Itself: Metabolic Psychiatry

Recommended Nutricost Premium MCT Oil Powder

Zero net carb MCT oil powder that mixes into coffee or smoothies to support ketosis and ketogenic diets.

Check Price →

Dr. Sethi founded what’s now called the metabolic psychiatry program at Stanford, and the framing matters. This isn’t about telling people with bipolar disorder to eat fewer carbs. It’s about positioning the ketogenic diet as a clinical metabolic intervention, the way you might think about a medication, with specific protocols, monitoring requirements, and a biological rationale.

The emerging theory, explained in a Stanford Medicine explainer from April 2025, centers on neuronal energy metabolism. Ketogenic therapy appears to increase the ratio of GABA to glutamate in neurons. GABA is inhibitory, glutamate is excitatory, and in certain psychiatric conditions there’s evidence of excessive neuronal firing. Shifting that balance could, in theory, reduce some of the hyperactivity patterns underlying symptoms. It’s a mechanistic hypothesis, not a proven pathway, but it’s specific enough to test, which is what’s now happening.

The Delphi Consensus: Why This Moment Is Different

Here’s what makes 2026 different from five years ago, when keto-for-mental-illness was mostly fringe speculation. In January 2026, researchers from Harvard Medical School, Stanford, and the University of Edinburgh published a formal Delphi consensus paper in Frontiers in Nutrition outlining best practices for using ketogenic metabolic therapy, or KMT, to treat serious mental illness.

A Delphi consensus isn’t a clinical trial. It’s a structured process where experts iteratively agree on recommendations based on available evidence and collective clinical experience. It’s what a field does when it’s ready to standardize, when there’s enough signal to start building protocol around. The fact that it now exists, with that institutional weight behind it, signals that metabolic psychiatry is past the “interesting hypothesis” stage and into something more organized.

The consensus covers things like patient selection criteria, how to manage the diet alongside psychiatric medications (some of which affect glucose metabolism), what monitoring is appropriate, and how to support adherence in a population that may already have cognitive and motivational challenges. These are practical, clinical questions. The kind researchers ask when they’re preparing to scale something, not just publish it.

What the Trials Will Actually Tell Us

The piece that’s genuinely exciting right now is timing. A University of Maryland clinical trial on ketogenic diet and mental health (NCT07116226) was actively enrolling as of April 2026, with completion estimated for July 2026. Results could be available before the end of this year. That trial, conducted with more rigor than the early pilot work, will give researchers a cleaner look at what’s actually happening, and give clinicians something firmer to stand on.

You might be wondering: why does this trial matter more than what’s already out there? The pilot data from Sethi’s study, while compelling, lacks a control arm. Without a comparison group, it’s hard to separate the effect of the diet from the effect of increased clinical attention, structured support, and the general metabolic improvements that tend to come with any meaningful dietary change. Larger, controlled trials are what move a therapy from “promising” to “practice-ready.”

We’re not there yet. I want to be honest about that. But “not there yet” is very different from “doesn’t work.” The field is in a serious investigational phase, with real institutional backing and real patients in trials, right now.

What This Means If You or Someone You Love Has a Serious Mental Illness

This is where I want to be careful, because I’ve sat with people who are desperate for something that works, and I know how easy it is to grab onto a headline. Here’s what I’d actually say across a desk.

Ketogenic diets are not without risk, especially for people on psychiatric medications. Valproate and some mood stabilizers interact with metabolic changes in ways that need monitoring. The diet is genuinely hard to sustain, and serious mental illness can make adherence harder still. Electrolyte shifts, initial fatigue, and gastrointestinal adjustment are common in the first weeks. None of this means it’s off the table, but it means it should be done with a clinical team, not from a YouTube video.

If you’re interested in KMT as an adjunct to existing treatment, the most productive thing you can do right now is look for practitioners with metabolic psychiatry experience, ask your psychiatrist whether a referral to a metabolic or nutrition-focused clinician makes sense, and watch for published results from active trials. The University of Maryland data, when it lands, will be worth paying attention to.

Don’t start a ketogenic diet for a serious psychiatric condition on your own. That’s not me being overly cautious. That’s just what the researchers doing this work would tell you too.

The RFK moment was messy and it set off a round of justifiable eye-rolling from people who’ve watched real science get flattened into slogans before. But underneath the noise, a genuine clinical movement is underway. It deserves neither uncritical excitement nor reflexive dismissal. The honest answer, right now, is that the science is serious, the results are early, and the next few months could tell us quite a bit more.

Sources

Photo: Zulfugar Karimov via Pexels

This article is for general informational purposes only and does not constitute medical or dietary advice. Always consult a licensed healthcare provider or registered dietitian before making significant changes to your diet, especially if you have a medical condition.